RU2020108574A - Терапевтическое средство, содержащее антагонист il-33, для лечения эндометриоза - Google Patents
Терапевтическое средство, содержащее антагонист il-33, для лечения эндометриоза Download PDFInfo
- Publication number
- RU2020108574A RU2020108574A RU2020108574A RU2020108574A RU2020108574A RU 2020108574 A RU2020108574 A RU 2020108574A RU 2020108574 A RU2020108574 A RU 2020108574A RU 2020108574 A RU2020108574 A RU 2020108574A RU 2020108574 A RU2020108574 A RU 2020108574A
- Authority
- RU
- Russia
- Prior art keywords
- endometriosis
- therapeutic agent
- treatment
- adenomyosis
- uterus
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title claims 10
- 239000003814 drug Substances 0.000 title claims 10
- 229940124597 therapeutic agent Drugs 0.000 title claims 10
- 239000005557 antagonist Substances 0.000 title claims 3
- 201000009274 endometriosis of uterus Diseases 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000031513 cyst Diseases 0.000 claims 4
- 230000002357 endometrial effect Effects 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1. Терапевтическое средство для лечения эндометриоза или аденомиоза матки, содержащее антагонист IL-33 в качестве активного ингредиента.
2. Терапевтическое средство по п. 1, характеризующееся тем, что указанное средство облегчает боль при эндометриозе или аденомиозе матки.
3. Терапевтическое средство по п. 1 или 2, характеризующееся тем, что указанное средство ингибирует рост эктопической эндометриальной ткани (включая кисты) при эндометриозе или аденомиозе матки.
4. Терапевтическое средство по любому из пп. 1-3, характеризующееся тем, что указанное средство ингибирует ангиогенез в эктопической эндометриальной ткани (включая кисты) при эндометриозе или аденомиозе матки.
5. Терапевтическое средство для лечения эндометриоза или аденомиоза матки по любому из пп. 1-4, характеризующееся тем, что указанное средство ингибирует фиброзирование или клеточную пролиферацию в эктопической эндометриальной ткани (включая кисты).
6. Терапевтическое средство по любому из пп. 1-5, характеризующееся тем, что указанное средство ингибирует адгезию эктопической эндометриальной ткани (включая кисты) при эндометриозе к различным органам.
7. Терапевтическое средство для лечения эндометриоза или аденомиоза матки по любому из пп. 1-6, характеризующееся тем, что антагонист IL-33 представляет собой анти-IL-33 антитело, антитело, направленное против рецептора IL-33, или растворимый рецептор IL-33.
8. Терапевтическое средство для лечения эндометриоза или аденомиоза матки по п. 7, характеризующееся тем, что IL-33 антитело представляет собой A10-1C04, A23-1A05, A25-2C02, A25-3H04 или A26-1F02.
9. Терапевтическое средство для лечения эндометриоза или аденомиоза матки по п. 7, характеризующееся тем, что растворимый рецептор IL-33 представляет собой sST2-Fc.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552594P | 2017-08-31 | 2017-08-31 | |
| US62/552,594 | 2017-08-31 | ||
| PCT/JP2018/032494 WO2019045075A1 (ja) | 2017-08-31 | 2018-08-31 | Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020108574A true RU2020108574A (ru) | 2021-08-30 |
| RU2020108574A3 RU2020108574A3 (ru) | 2021-09-16 |
| RU2791705C2 RU2791705C2 (ru) | 2023-03-13 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL272864B1 (en) | 2023-11-01 |
| AU2018325645B2 (en) | 2024-10-10 |
| TW202306586A (zh) | 2023-02-16 |
| WO2019045075A1 (ja) | 2019-03-07 |
| JP2024045481A (ja) | 2024-04-02 |
| JP7177446B2 (ja) | 2022-11-24 |
| TWI825025B (zh) | 2023-12-11 |
| AU2018325645A1 (en) | 2020-02-27 |
| BR112020003458A2 (pt) | 2020-08-25 |
| MX2020002086A (es) | 2020-10-28 |
| US20220372130A1 (en) | 2022-11-24 |
| CN111107875A (zh) | 2020-05-05 |
| CA3074421A1 (en) | 2019-02-07 |
| TW201919706A (zh) | 2019-06-01 |
| KR20200044812A (ko) | 2020-04-29 |
| RU2020108574A3 (ru) | 2021-09-16 |
| CN115920031A (zh) | 2023-04-07 |
| JPWO2019045075A1 (ja) | 2020-08-20 |
| CN115920041A (zh) | 2023-04-07 |
| ZA202001256B (en) | 2023-10-25 |
| EP3677281A4 (en) | 2021-05-12 |
| CN115920032A (zh) | 2023-04-07 |
| KR102674516B1 (ko) | 2024-06-17 |
| IL272864A (en) | 2020-04-30 |
| US11492398B2 (en) | 2022-11-08 |
| PH12020500400A1 (en) | 2021-01-04 |
| IL272864B2 (en) | 2024-03-01 |
| JP7441473B2 (ja) | 2024-03-01 |
| JP2022190064A (ja) | 2022-12-22 |
| EP3677281A1 (en) | 2020-07-08 |
| US20200190182A1 (en) | 2020-06-18 |
| SG11202001786PA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125254T1 (el) | Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| JP2016520558A5 (ru) | ||
| RS54398B1 (en) | THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE | |
| MX363697B (es) | Formulaciones orales de derivados de pirrolidina. | |
| TR201908600T4 (tr) | Hastalıkların tedavisine yönelik (11.beta.,17.beta.)-17-hidroksi-11-[4-(metilsülfonil)fenil]-17-(pentaflorometil)estra-4,9-dien-3-on. | |
| MX2021005945A (es) | Ureas ciclicas. | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| TN2020000009A1 (en) | Estrogen receptor modulators | |
| MA52756A (fr) | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression | |
| RU2020108574A (ru) | Терапевтическое средство, содержащее антагонист il-33, для лечения эндометриоза | |
| MA55142A (fr) | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation | |
| TN2017000445A1 (en) | Drippable ophthalmic bimatoprost gel | |
| PH12015502326A1 (en) | Progesterone receptor antagonist dosage form | |
| EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора | |
| CL2003001544A1 (es) | Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l | |
| DE602005023742D1 (de) | Formulierung von 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-on mit verzögerter freisetzung | |
| MX2014009494A (es) | Dispositivo cervico uterino que incrementa la protección del riesgo de contraer cáncer cervico uterino. | |
| ZA202200331B (en) | Naltrexone formulation | |
| RU2020121929A (ru) | Фармацевтические комбинации | |
| NL153533B (nl) | Werkwijze voor het bereiden van 1,2-difenyl-3,5-dioxo-4-(3'-oxobutyl)-pyrazolidine. | |
| MX2019003815A (es) | Composiciones farmaceuticas de antagonista del 5-ht6. | |
| BR112017016689A2 (pt) | comprimido e método para preparar o mesmo | |
| RU2013153078A (ru) | Лекарственная форма натамицина и нифуратела для лечения урогенитальных грибковых заболеваний при беременности |